



Prof. Dr. med. Ulrich Marcus Hentrich

Originalarbeiten, Fallberichte und Reviews

1. von Lilienfeld-Toal M, Berger B, Christopeit M, Hentrich M, Heussel CP, Kalkreuth J, Klein M, Kochanek M, Penack O, Hauf E, Rieger C, Silling G, Vehreschild M, Weber T, Wolf H-H, Lehnert N, Schalk E, Mayer K. Community acquired respiratory virus (CRV) infections in cancer patients - guideline on diagnosis and management by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). *Eur J Cancer* 2016;67:200-12
2. Straka C, Liebisch P, Salwender H, Hennemann B, Metzner B, Knop S, Adler-Reichel S, Gerecke G, Wandt H, Bentz M, Bruemmendorf TH, Hentrich M, Pfreundschuh M, Wolf H-H, Sezer O, Bargou R, Jung W, Trümper L, Hertenstein B, Heidemann E, Bernhard H, Lang N, Frickhofen N, Hebart H, Schmidmaier R, Sandermann A, Dechow T, Reichle A, Schnabel B, Schäfer-Eckart K, Langer C, Gramatzki M, Hinke A, Emmerich B, Einsele H, for the DSMM Study Group. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: Long-term outcome of a randomized trial. *Haematologica* 2016;101(11):1398-1406
3. Hausmann A, Fischer N, Breitkopf S, Menne F, Jess K, Schmidmayr S, Wendtner CM, Hentrich M. Severe motoric aphasia following reinfusion of cryopreserved autologous stem cells after myeloablative conditioning. *Transfusion* 2016;56(10):2615-7
4. Biehl LM, Huth A, Panse J, Krämer C, Hentrich M, Engelhardt M, Schäfer-Eckart K, Kofla G, Kiehl M, Wendtner CM, Karthaus M, Ullmann AJ, Hellmich M, Christ H, Vehreschild MJ. A randomized trial on chlorhexidine dressings for the prevention of catheter-related bloodstream infections in neutropenic patients. *Ann Oncol.* 2016;27(10):1916-22
5. Seidel C, Oechsle K, Lorch A, Dieing A, Hentrich M, Hornig M, Grünwald V, Cathomas R, Meiler J, de Wit M, Bokemeyer C. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel (GOP) in cisplatin-refractory germ cell cancer in routine care - Registry data from an outcomes research project of the German Testicular Cancer Study Group (GTCSG). *Urol Oncol* 2016;34(4):168.e21-8
6. Hoffmann C, Schommers P, Wolf E, Müller M, Schultze A, Krznaric I, Stoehr A, Wolf T, Fätkenheuer G, Stier B, Wyen C, and Hentrich M. CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or Non Hodgkin Lymphoma. *AIDS* 2016;30(5):753-60
7. Jokisch J-F, Ganswindt U, Hentrich M, Stief C, Karl A. Harnblasenkrebs. *MMW Fortschritte der Medizin* 2015;157:42-45
8. Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O, Biehl L, Cornely OA. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). *Ann Hematol* 2015;94(9):1441-50
9. Schommers P*, Hentrich M*, Hoffmann C, Gillor D, Zoufaly A, Jensen B, Bogner JR, Thoden J, Wasmuth JC, Wolf T, Oette M, Müller M, Esser S, Vehreschild JJ, Fätkenheuer G, Wyen C. Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. *Br J Haematol* 2015;168(6):806-10
(* geteilte Erstautorschaft)

10. Hoffmann C*, Hentrich M*, Gillor D, Behrens G, Jensen B, Stoehr A, Esser S, van Lunzen J, Krznic I, Müller M, Oette M, Hensel M, Thoden J, Fätkenheuer G, Wyen C. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study. *HIV Med* 2015;16(4):261-4 (* geteilte Erstautorschaft)
11. Straka C, Salwender H, Schnabel B, Sandherr M, Wandt H, Hübel K, Scheid C, Metzner B, Hentrich M, Franke D, Weidenegger G, Freund M, Sezer O, Einsele H, Hinke A, Emmerich B. Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma. *Leuk Lymph* 2015; 56(2):368-76
12. Morris C, de Wreede L, Scholten M, Brand R, van Biezen A, Sureda A, Dickmeiss E, Trneny M, Apperley J, Chiusolo P, van Imhoff GW, Lenhoff S, Martinelli G, Hentrich M, Pabst T, Onida F, Quinn M, Kroger N, de Witte T, Ruutu T. Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. *Transfusion* 2014;54(10):2514-22
13. Hentrich M, Hoffmann C, Mosthaf F, Müller M, Siehl J, Wyen C, Hensel M. Therapy of HIV-associated lymphoma—recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG). *Ann Hematol* 2014;93:913–921
14. Berger LA, Bokemeyer C, Lorch A, Hentrich M, Kopp HG, Gauler TC, Beyer J, de Wit M, Mayer F, Boehlke I, Oing C, Honecker F, Oechsle K. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). *J Cancer Res Clin Oncol* 2014;140(7):1211-20
15. Xicoy B, Ribera JM, Müller M, García O, Hoffmann C, Oriol A, Hentrich M, Grande C, Wasmuth JC, Esteve J, van Lunzen J, Del Potro E, Knechten H, Brunet S, Mayr C, Escoda L, Schommers P, Alonso N, Vall-Llovera F, Pérez M, Morgades M, González J, Fernández A, Thoden J, Gökbuget N, Hoelzer D, Fätkenheuer G, Wyen C. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. *Leuk Lymph* 2014;55(10):2341-8.
16. Fiegl M, Unterhalt M, Kern W, Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Schöndube D, Serve H, Reichle A, Hentrich M, Schiel X, Sauerland C, Heinecke A, Rieger C, Beelen D, Berdel WE, Büchner T, Hiddemann W. Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG. *Leukemia* 2014;28(5):1001-7.
17. Penack O, Becker C, Buchheidt D, Christopheit M, Kiehl M, von Lilienfeld-Toal M, Hentrich M, Reinwald M, Salwender H, Schalk E, Schmidt-Hieber M, Weber T, Ostermann H. Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). *Ann Hematol* 2014;93(7):1083-95
18. Hentrich M, Schalk E, Schmidt-Hieber M, Chaberny I, Mousset S, Buchheidt D, Ruhnke M, Penack O, Salwender H, Wolf HH, Christopheit M, Neumann S, Maschmeyer G, Karthaus M. Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. *Ann Oncol* 2014;25(5):936-47.
19. Gerl A, Hentrich M. Aktuelle Therapie- und Nachsorgestrategien bei Hodentumoren. *InFo Onkologie* 2014;4:38-45.

21. Re A, Cattaneo C, Skert C, Balsalobre P, Michieli M, Bower M, Ferreri AJ, Hentrich M, Ribera JM, Allione B, Schommers P, Montoto S, Almici C, Ferremi P, Mazzucato M, Gattillo S, Casari S, Spina M, Diez-Martin JL, Tirelli U, Rossi G. Stem cell mobilization in HIV seropositive patients with lymphoma. *Haematologica* 2013;98(11):1762-8.
22. Schommers P, Wyen C, Hentrich M, Gillor D, Zoufaly A, Jensen B, Bogner JR, Thoden J, Wasmuth JC, Fätkenheuer G, Hoffmann C. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. *AIDS* 2013;27:842-5
23. Fegg MJ, Brandstätter M, Kögler M, Hauke G, Rechenberg-Winter P, Fensterer V, Küchenhoff H, Hentrich M, Belka C, Borasio GD. Existential behavioural therapy for informal caregivers of palliative patients: a randomised controlled trial. *Psychooncology* 2013;22:2079-86
24. Vehreschild MJ, Vehreschild JJ, Hübel K, Hentrich M, Schmidt-Hieber M, Christopeit M, Maschmeyer G, Schalk E, Cornely OA, Neumann S. Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Oncol* 2013;24:1189-202
25. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Claßen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germá Lluch JR, Gietema JA, Gillissen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LH, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. *Ann Oncol* 2013;24:878-8
26. Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, Fätkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schürmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A, Arasteh K, Hoffmann C. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. *J Clin Oncol* 2012;30:4117-23
27. Hentrich M, Gerl A. Primärtherapie von Keimzelltumoren des Hodens. *Krebsmedizin* 2012;21(2):62-74
28. Gerl A, Hentrich M. Nachsorge von Patienten mit Hodentumoren. *Krebsmedizin* 2012;21(2):75-82
29. Wyen C, Jensen B, Hentrich M, Siehl S, Sabranski M, Esser S, Gillor D, Müller M, van Lunzen J, Wolf T, Bogner J, Wasmuth JC, Thoden J, Christ H, Fätkenheuer G, Hoffmann C. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. *AIDS* 2012;26:457-464
30. Scherberich JE, Kornmeier A, Wiemer J, Hentrich M, Kremer M, Amann K. Nephrotisches Syndrom, Niereninsuffizienz und Raumforderungen in Leber und Milz. *Nephrologe* 2012;7:423-7
31. Rölling C, Brandts C, Shaid S, Hentrich M, Krämer A, Junghanß C, Schleyer E, Müller-Tidow C, Berdel WE, Ritter B, Pflüger KH, Kramer M, Haibach M, Ehninger G, Serve H, Krause S. Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. *Leuk Lymph* 2012;53:1062-7

32. Straka C, Straka C, Sandherr M, Salwender H, Wandt H, Metzner B, Hübel K, Silling G, Hentrich M, Franke D, Schwerdtfeger R, Freund M, Sezer O, Giagounidis A, Ehninger G, Grimminger W, Engert A, Schlimok G, Scheid C, Hellmann P, Heinisch H, Einsele H, Hinke A, Emmerich B. Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. *Blood* 2011;177:2121-8
33. Karthaus M, Hentrich M. Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis. *Mycoses* 2011;54 Suppl 1:1-6
34. Penack O, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Massenkeil G, Hentrich M, Salwender H, Wolf HH, Ostermann H. Management of sepsis in neutropenic patients: guidelines of the infectious diseases working party of the German Society of Hematology and Oncology. *Ann Oncol* 2011;22:1019-29
35. Hentrich M, Mosthaf F. Maligne Lymphome bei HIV-Infektion. *InFoOnkologie* 2010;13:46-52
36. Hentrich M, Schiel X, Niedermeier A, Lutz L, Rupec R, Stief C, Bogner J, Karthaus M, Gerl A. Successful salvage high-dose chemotherapy and autologous stem-cell transplantation in HIV-related germ-cell tumor. [Ann Oncol](#). 2009;20:1900-1
37. Braess J, Spiekermann K, Staib P, Gruneisen A, Wormann B, Ludwig WD, Serve H, Reichle A, Peceny R, Oruzio D, Schmid C, Schiel X, Hentrich M, Sauerland C, Unterhalt M, Fiegl M, Kern W, Buske C, Bohlander S, Heinecke A, Baurmann H, Beelen DW, Berdel WE, Buchner T, Hiddemann W. Dose-dense induction with sequential-high-dose cytarabine and mitoxantrone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de-novo acute myeloid leukaemia – a pilot study of the AML-CG. *Blood* 2009;113:3903-10
38. Díez-Martín JL, Balsalobre P, Re A, Michieli M, Ribera J, Canals C, Conde E, Rosselet A, Gabriel I, Varela R, Allione B, Cwynarski K, Genet P, Espigado I, Biron P, Schmitz N, Hunter AE, Ferrant A, Guillelm G, Hentrich M, Jurado M, Fernández P, Serrano D, Rossi G, Sureda A. Comparable survival between HIV positive and HIV negative non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell Transplantation. *Blood* 2009;113:6011-4
39. Schlemmer M, Kühl M, Schalhorn A, Rauch J, Jauch K-W, Hentrich M. Tissue levels of 5,10 methylenetetrahydrofolate and tetrahydrofolate in patients with colorectal carcinoma following Infusion of folinic acid at various dose levels. *Clin Cancer Res* 2008;14:7930-4
40. Hentrich M, Schiel X, Scheidt B, Reitmeier M, Lutz L. Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer. *Acta Oncol* 2008;47:155-6
41. Schmid C, Schleuning M, Hentrich M, Markl GE, Gerbitz A, Tischer J, Ledderose G, Oruzio D, Hiddemann W, Kolb H-J. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. *Bone Marrow Transplant* 2008;41:721-7
42. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Röthling N, Peschel C, Lordick F. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. *Ann Oncol* 2007;18:1673-9
43. Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf H-H, Einsele H, Volpert S, Heinecke A, Berdel WE, Kienast J. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. *Br J Haematol* 2007;138:330-7

44. Hentrich M, Fehnle K, Ostermann H, Kienast J, Cornely O, Salat C, Übelacker R, Buchheidt D, Behre G, Hiddemann W, Schiel X. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multi-center trial. *Crit Care Med* 2006;34:1319-25
45. Hentrich M, Maretta L, Chow KU, Bogner J, Schürmann D, Neuhoﬀ P, Jäger H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weiß R, Rockstroh J, Arasteh K, Mitrou P. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. *Ann Oncol* 2006;17:914-9 sowie *Ann Oncol SA Excerpts Edition* 2006;3:249-54
46. Schiel X, Link H, Maschmeyer G, Glaß B, Cornely OA, Buchheidt D, Wilhelm M, Silling G, Helmerking M, Hiddemann W, Ostermann W, Hentrich M, for the Study Group of the Paul-Ehrlich-Society. A prospective, randomized multicenter trial of a sequential empirical antibiotic and antifungal therapy for febrile neutropenic cancer patients: Results of the Paul-Ehrlich-Society for Chemotherapy (PEG) Multicenter Trial II. *Infection* 2006;34:118-126
47. Weiß R, Mitrou P, Arastéh K, Schuermann D, Hentrich M, Duehrsen U, Sudeck H, Schmidt-Wolf IG, Anagnostopoulos I, Huhn D. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival - Results of the German Multicenter Trial. *Cancer* 2006;106:1560-8
48. Hoffmann C, Wolf E, Wyen C, Fätkenheuer G, van Lunzen J, Stellbrink H-J, Stoehr A, Plettenberg A, Jaeger H, Noppeney R, Hentrich M, Goekbuget N, Hoelzer D, Horst H-A. Aids-associated Burkitt- or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. *Leuk Lymph* 2006;47:1872-80
49. Hentrich M, Fegg M, Jost Ch, Meiler S, Gerl A. Smoking Cessation in Long-Term Survivors of Germ Cell Tumor (GCT). *J Cancer Res Clin Oncol* 2006;132:557-60
50. Schlemmer M, Wendtner C-M, Falk M, Licht T, Abdel-Rahman S, Baumert J, Straka C, Hentrich M, Salat C, Hiddemann W, Issels RD. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral stem cell rescue (PBSCR) in chemosensitive patients with metastatic soft tissue sarcomas. *Oncology* 2006;71:32-9
51. Reimer P, Hentrich M. Peripheral T-cell lymphoma: diagnosis and treatment. *Dtsch Med Wochenschr* 2006;131:685-90 sowie *Pharma Fokus Onkologie* 2006;3(1):13-19
52. Hentrich M, Oruzio D, Jäger G, Schlemmer M, Schleuning M, Schiel X, Hiddemann W, Kolb HJ. Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. *Br J Haematol* 2005;128:66-72
53. Hentrich M, Weber N, Bergsdorf T, Bernhard Liedl B, Hartenstein R, Gerl A. Management and Outcome of Bilateral Testicular Germ Cell Tumors: 25 year experience in Munich. *Acta Oncol* 2005;44:529-36
54. Ballova V, Ruffer JU, Haverkamp H, Pfistner B, Müller-Hermelink HK, Dühmke E, Worst P, Wilhelm M, Naumann R, Hentrich M, Eich HAT, Josting A, Löffler M, Diehl V, Engert A. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). *Ann Oncol* 2005;16:124-31
55. Lordick F, Lorenzen S, Stollfuss J, Vehling-Kaiser U, Kullmann F, Hentrich M, Zumschlinge R, Dietzfelbinger H, Thoedtmann J, Hennig M, Seroneit T, Bredenkamp R, Duyster J, Peschel C. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. *Br J Cancer* 2005;93:190-4

56. Lordick F, Hentrich M, Decker T, Hennig M, Pohlmann H, Hartenstein R, Peschel C. Ultrasound screening for internal jugular vein thrombosis aids the detect of central venous catheter-related infections in patients with haematological diseases: a prospective observational study. *Br J Haematol* 2003;120:1073-8
57. Kropff MH, Lang N, Bisping G, Domine N, Innig G, Hentrich M, Mitterer M, Sudhoff T, Fenk R, Straka C, Heinecke A, Koch OM, Ostermann H, Berdel WE, Kienast J. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. *Br J Haematol* 2003;122:607-16
58. Bittmann I, Hentrich M, Bise K, Kolb HJ, Löhrs U. Endothelial cells but not epithelial cells or cardiomyocytes are partially replaced by donor cells after allogeneic bone marrow and stem cell transplantation. *J Hematother Stem Cell Res* 2003;12:359-66
59. Pihusch R, Salat C, Göhring P, Hentrich M, Wegner H, Pihusch M, Hiller E, Kolb HJ, Ostermann H. Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft-versus-host disease of the gut. *Br J Haematol* 2002;117:469-76
60. Kollmannsberger C, Rick O, Klaproth H, Kubin T, Sayer H, Hentrich M, Welslau M, Mayer F, Kuczyk M, Spott C, Kanz L, Bokemeyer C. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: A phase II study of the German Testicular Cancer Study Group. *Br J Cancer* 2002;87:729-32
61. Hentrich M, Stötzer OJ, Salat C, Ledderose G. Chronic myeloid leukemia – case report. *Dtsch Med Wochenschr* 2002;127:2617
62. Stötzer OJ, Hentrich M, Salat C. Chronic myeloid leukemia – pathophysiology and diagnosis. *Dtsch Med Wochenschr* 2002;127:2618-20
63. Stötzer OJ, Hentrich M, Salat C. Chronic myeloid leukemia – treatment. *Dtsch Med Wochenschr* 2002;127:2621-4
64. Munker R, Brack N, Hentrich M, Kolb HJ. Transplantation von Blutstammzellen heute. Indikationen, Komplikationen und aktuelle Entwicklungen. *Kliniker* 2001;7/8:218-25
65. Hentrich M, Rockstroh J, Sandner R, Brack N, Hartenstein R. Acute myelogenous leukaemia and myelomonocytic blast crisis following polycytemia vera in HIV positive patients: report of cases and review of the literature. *Ann Oncol* 2000;11:195-200
66. Hentrich M, Jäger H, Hartenstein R. HIV-assoziierte Malignome. *Onkologie* 1999;22:240-4
67. Hentrich M, Hartenstein R. Behandlung maligner Körperhöhlenergüsse. *Internist* 1997;8:794-804 sowie *Onkologie* 1997;3:163-73
68. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W. Late relapse of germ cell tumors after cisplatin-based chemotherapy. *Ann Oncol* 1997;8:41-7
69. Hentrich M, Brack NG, Schmid P, Schuster T, Clemm C, Hartenstein R. Testicular germ cell tumors in patients with human immunodeficiency virus infection. *Cancer* 1996;77:2109-16
70. Hentrich M, Meister P, Brack NG, Lutz L, Hartenstein R. Adult Wilms` tumor. Report of two cases and review of the literature. *Cancer* 1995;75:545-51
71. Hentrich M, Hartenstein R. Wilms` tumor in adults. *Onkologie* 1995;18:310-5

72. Gerl A, Clemm C, Hentrich M, Hartenstein R, Wilmanns W. Etoposide, cisplatin, bleomycin, and cyclophosphamide (ECBC) as first line chemotherapy for poor-risk non-seminomatous germ cell tumors. *Acta Oncol* 1993;32:541-6
73. Meister P, Nerl C, Pickl-Pfeffer S, Brack N, Hentrich M, Pohlmann H, Horn J. Pilzsepsis bei unreifzelliger Leukämie. *MMW* 1993;135(47):647-50
74. Peikert A, Hentrich M, Ochs G. Topical 0,025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course. *J Neurol* 1991;238:452-6

Buch-Herausgeberschaft

Marcus Hentrich, Stefan K. Barta (Editors). HIV-associated Hematological Malignancies. Springer International Publishing Switzerland 2016

Buchbeiträge

1. Hentrich M, Spina M, Montoto S. HIV-associated Hodgkin Lymphoma. In: Hentrich M, Barta SK (Editors). HIV-associated Hematological Malignancies. Springer International Publishing Switzerland 2016:119-32
2. Re A, Krishnan A, Hentrich M. Autologous stem cell transplantation. In: Barta S, Hentrich M (Editors). HIV-associated Hematological Malignancies. Springer International Publishing Switzerland 2016:153-64
3. Hentrich M. Infection prophylaxis. In: Barta S, Hentrich M (Editors). HIV-associated Hematological Malignancies. Springer International Publishing Switzerland 2016:223-6
4. Häbe S, Hellmuth J, Engel N, Rank A, Hentrich M, Ostermann H. Hodgkin Lymphom. In: Dreyling M (Hrsg). Maligne Lymphome. Empfehlungen zur Diagnostik, Therapie und Nachsorge (10. Auflage), Zuckschwerdt Verlag, München 2015:60-76
5. Hentrich M, Dreyling M, Kremer M, Zettl F, Oduncu F, Keller U. T-Zell-Lymphome. In: Dreyling M (Hrsg). Maligne Lymphome. Empfehlungen zur Diagnostik, Therapie und Nachsorge (10. Auflage), Zuckschwerdt Verlag, München 2015:159-168
6. Keller U, Hentrich M, Sotlar K, Dreyling M. Burkitt Lymphom. In: Dreyling M (Hrsg). Maligne Lymphome. Empfehlungen zur Diagnostik, Therapie und Nachsorge (10. Auflage), Zuckschwerdt Verlag, München 2015:169-173
7. Hentrich M, Schmidmaier R, Sotlar K, Starck M, Schneller F, Oduncu F. Maligne Lymphome im Rahmen der HIV-Erkrankung und Posttransplantationslymphome. In: Dreyling M (Hrsg). Maligne Lymphome. Empfehlungen zur Diagnostik, Therapie und Nachsorge (10. Auflage), Zuckschwerdt Verlag, München 2015:174-184
8. Starck M, Sotlar K, Schneider S, Hentrich M, Subklewe M, Spiekermann K. Allgemeine Diagnostik. In: Spiekermann K (Hrsg): Leukämien, myelodysplastische Syndrome und myeloproliferative Neoplasien (4. Auflage), Zuckschwerdt Verlag, München 2015:1-18
9. Stark M, Subklewe M, Schmid C, Schneider S, Hentrich M, Schneller K, Spiekermann K, Wendtner C. Akute lymphoblastische Leukämie (ALL) bei Erwachsenen. In: Spiekermann K (Hrsg): Leukämien, myelodysplastische Syndrome und myeloproliferative Neoplasien (4. Auflage), Zuckschwerdt Verlag, München 2015:75-99

10. Hentrich M, Tischer J, Sandherr M. Virustatische Prophylaxe und Therapie. In: Ostermann H (Hrsg). Supportive Maßnahmen in der Hämatologie und Onkologie (2. Auflage). Zuckschwerdt Verlag, München 2014:24-31
11. Abenhardt W, Hentrich M, Oduncu F. Behandlung von Übelkeit und Erbrechen in der Onkologie. In: Ostermann H (Hrsg). Supportive Maßnahmen in der Hämatologie und Onkologie (2. Auflage). Zuckschwerdt Verlag, München 2014:58-76
12. Hentrich M, Lutz L, Oduncu F. Prophylaxe und Therapie des Tumorlyse-Syndroms. In: Ostermann H (Hrsg). Supportive Maßnahmen in der Hämatologie und Onkologie (2. Auflage). Zuckschwerdt Verlag, München 2014:77-80
13. Bausewein C, Delagardelle I, Hentrich M, Langenbach R, Strohscheer I. Gastrointestinale Symptome. In: Aulbert E, Nauck F, Radbruch L (Hrsg.). Lehrbuch der Palliativmedizin (3. Auflage), Schattauer-Verlag, Stuttgart 2012:265-300
14. Hentrich M, Starck M, Walther J, Subkewe M, Nerl C, Oduncu F. Maligne Lymphome im Rahmen der HIV-Erkrankung und Posttransplantationslymphome. In: Dreyling M (Hrsg). Maligne Lymphome. Empfehlungen zur Diagnostik, Therapie und Nachsorge (9. Auflage), Zuckschwerdt Verlag, München 2012:181-188
15. Hentrich M, Zewen S, Dreyling M, Subklewe M, Abedinpour F, Nerl C, Oduncu F. T-Zell-Lymphome. In: Dreyling M (Hrsg). Maligne Lymphome. Empfehlungen zur Diagnostik, Therapie und Nachsorge (9. Auflage), Zuckschwerdt Verlag, München 2012:170-176
16. Engel N, Rank A, Niemöller O, Hiller E, Hentrich M, Ostermann H. Morbus Hodgkin. In: Dreyling M (Hrsg). Maligne Lymphome. Empfehlungen zur Diagnostik, Therapie und Nachsorge (9. Auflage), Zuckschwerdt Verlag, München 2012:58-75
17. Keller U, Dickhut A, Will T, Hentrich M, Dreyling M. Burkitt Lymphom. In: Dreyling M (Hrsg). Maligne Lymphome. Empfehlungen zur Diagnostik, Therapie und Nachsorge (9. Auflage), Zuckschwerdt Verlag, München 2012:177-180
18. Hentrich M. Intensive Therapie des Morbus Hodgkin bei HIV – ein Risiko? In: Hoffmann/Jäger (Hrsg.) HIV/AIDS besiegen: Visionen der Heilung. AIDS und HIV-Infektionen in Klinik und Praxis, Monographiereihe, Band 13. Wiley-Blackwell, Berlin 2010:34
19. Linke, Fischer N, Franke D, Hentrich M. AL-Amyloidosen. In: Straka C, Dietzfelbinger H (Hrsg). Multiples Myelom. Empfehlungen zur Diagnostik, Therapie und Nachsorge (3. Auflage), Zuckschwerdt Verlag, München 2009: 264-75
20. Hentrich M, Lang N, Tischer J, Straka C, v. Schilling C, Stötzer O, Kolb H-J. Allogene Stammzelltransplantation. In: Straka C, Dietzfelbinger H (Hrsg). Multiples Myelom. Empfehlungen zur Diagnostik, Therapie und Nachsorge (3. Auflage), Zuckschwerdt Verlag, München 2009:147-52
21. Straka C, Hentrich M, Fischer N, Kolb H-J, Oduncu F, Schmidmaier R, Emmerich B. Autologe Blutstammzelltransplantation. In: Straka C, Dietzfelbinger H (Hrsg). Multiples Myelom. Empfehlungen zur Diagnostik, Therapie und Nachsorge (3. Auflage), Zuckschwerdt Verlag, München 2009:136-46
22. Adorf D, Hentrich M, Schneider S, Christ O, Spiekermann C, Nerl C. Allgemeine Diagnostik. In: Hiddemann W, Braess J (Hrsg). Leukämien, Myelodysplastische und Myeloproliferative Syndrome. Empfehlungen zur Diagnostik, Therapie und Nachsorge (3. Auflage), Zuckschwerdt Verlag, München 2009:1-16

23. Hentrich M, Schmid C, Kolb HJ, Petrides P. Stammzelltransplantation bei chronisch myeloproliferativen Erkrankungen. In: Hiddemann W, Braess J (Hrsg). Leukämien, Myelodysplastische und Myeloproliferative Syndrome. Empfehlungen zur Diagnostik, Therapie und Nachsorge (3. Auflage), Zuckschwerdt Verlag, München 2009:190-1
24. Hentrich M, Masuhr A, Wyen C, Wolf T, Rockstroh J, Nickelsen M, Schürmann D, Kloenne U, Weiss R, Knechten H; Mosthaf F; Arastéh K, Fätkenheuer G, Mitrou P, Hoffmann C. HIV-assoziiertes Morbus Hodgkin: Zwischenergebnisse einer multizentrischen Therapieoptimierungsstudie. In: Hoffmann/Jäger (Hrsg.) AIDS 2008. PräventionsBotschaften MenschenRechte TherapieFortschritte. AIDS und HIV-Infektionen in Klinik und Praxis, Monographiereihe, Band 12. Wiley-Blackwell, Berlin 2008:34-5
25. Gerl A, Hentrich M, Weiss M, Pöllinger B, Barba M, Liedl B, Seitz M, Clemm C. Hodentumoren. In: Treiber U (Hrsg). Urogenitale Tumoren. Empfehlungen zur Diagnostik, Therapie und Nachsorge (4. Auflage), Zuckschwerdt Verlag, München 2008:182-205
26. Hentrich M, Fend F, Walther J, Starck M, Nerl C. Maligne Lymphome im Rahmen der HIV-Erkrankung und Posttransplantationslymphome. In: Dreyling M (Hrsg). Maligne Lymphome. Empfehlungen zur Diagnostik, Therapie und Nachsorge (8. Auflage), Zuckschwerdt Verlag, München 2008:167-74
27. Nerl C, Abedinpour F, Dreyling M, Zewen S, Hentrich M. Periphere T-Zell-Lymphome. In: Dreyling M (Hrsg). Maligne Lymphome. Empfehlungen zur Diagnostik, Therapie und Nachsorge (8. Auflage), Zuckschwerdt Verlag, München 2008:140-7
28. Hentrich M. HIV-assoziiertes Morbus Hodgkin. Kongreßband zur 2. Münchner AIDS-Werkstatt, MedReport (Suppl). Blackwell Verlag 2007:20
29. Mosthaf FA, Weiß R, Hentrich M. Malignome richtig behandeln. In: Hoffmann/Jäger (Hrsg.) AIDS 2006. Wunschwelt Heilung – Evidenz für Fortschritt oder Stillstand? AIDS Monographien, Band 11. 2006 mic – management information center GmbH, Landsberg/Lech 2006:50-51
30. Hentrich M, Jäger H, Munker R, Brack N, Hartl H, Hartenstein R. Akute Leukämien bei HIV-infizierten Patienten. In: Hoffmann/Jäger (Hrsg.) AIDS – Die Auseinandersetzung geht weiter (verlag moderne industrie Landsberg/Lech) 2002:143-8
31. Hentrich M, Stötzer O, v. Schilling Ch, Straka C, Schleuning M, Kolb HJ. Allogene Stammzelltransplantation. In: Bartl , Dietzfelbinger H (Hrsg). Multiples Myelom. Empfehlungen zur Diagnostik, Therapie und Nachsorge (2. Auflage), Zuckschwerdt Verlag, München 2002:116-21
32. Straka C, v. Schilling Ch, Hentrich M, Waterhouse C, Kolb HJ, Emmerich B. Autologe hämatopoetische Transplantation. In: Bartl, Dietzfelbinger H (Hrsg). Multiples Myelom. Empfehlungen zur Diagnostik, Therapie und Nachsorge (2. Auflage), Zuckschwerdt Verlag, München 2002:106-15
33. Hartenstein R, Hentrich M. Behandlung maligner Körperhöhlenergüsse und intraperitoneale Chemotherapie. In: Huhn/Herrmann (Hrsg.) Medikamentöse Therapie maligner Erkrankungen (4. Auflage), Urban & Fischer, München 2001:481-94
34. Hartenstein R, Hentrich M. Behandlung des zytostatikabedingten Erbrechens. In: Huhn/Herrmann (Hrsg.) Medikamentöse Therapie maligner Erkrankungen (4. Auflage), Urban & Fischer, München 2001:495-506
35. Hartenstein R, Hentrich M. Onkologische Notfallsituationen. In: Huhn/Herrmann (Hrsg.) Medikamentöse Therapie maligner Erkrankungen (4. Auflage), Urban & Fischer, München 2001:517-34

36. Hentrich M, Lutz L. Prophylaxe und Therapie des Tumorlyse-Syndroms. In: Heinemann V (Hrsg). Supportive Maßnahmen und symptomorientierte Therapie in der Hämatologie und Onkologie (1. Auflage), Zuckschwerdt Verlag, München 2001:104-6
37. Abenhardt W, Bosse D, Hentrich M., Brack N. Behandlung maligner Ergüsse. In: Heinemann V (Hrsg). Supportive Maßnahmen und symptomorientierte Therapie in der Hämatologie und Onkologie (1. Auflage), Zuckschwerdt Verlag, München 2001:169-78
38. Abenhardt W, Bosse D, Dietzfelbinger H, Hentrich M, Hesse. Behandlung von Übelkeit und Erbrechen in der Onkologie. In: Heinemann V (Hrsg). Supportive Maßnahmen und symptomorientierte Therapie in der Hämatologie und Onkologie (1. Auflage), Zuckschwerdt Verlag, München 2001:80-9
39. Hartenstein R, Bausewein C, Hentrich M, Lutz L, Reitmeier M. Gastrointestinale Symptome. In: Aulbert/Zech (Hrsg.) Lehrbuch der Palliativmedizin (1. Auflage), Schattauer-Verlag, Stuttgart 1997:531-55
40. Hentrich M, Brack N, Jäger H, Hartenstein R. HIV-Infektion und Keimzelltumoren des Hodens. In: Jäger (Hrsg.) AIDS – Management der Erkrankung (Ecomed Landsberg/Lech) 1996:133-4
41. Clemm C, Gerl A, Hentrich M, Wilmanns W. Chemotherapy in stage IIC-IV seminoma. In: Schnorr D, Loening SA, Weißbach L (Hrsg.) Hodentumoren. Blackwell Wissenschaftsverlag Berlin 1995:199
42. Gerl A, Clemm C, Hentrich M, Hartenstein R, Kohl P, Wilmanns W. Combination chemotherapy with etoposide, cisplatin, bleomycin and cyclophosphamide for advanced metastatic non-seminomatous germ cell tumors. In: Banzet P, Holland JF, Khayat D, Weil M (Eds.) Cancer treatment. An Update. Springer-Verlag, Paris 1994:499-502
43. Gerl A, Clemm C, Hentrich M, Kohl P, Hartenstein R, Wilmanns W. Four drug combination chemotherapy consisting of etoposide, cisplatin, bleomycin and cyclophosphamide for advanced metastatic nonseminomatous germ cell tumors. In: III. Advances in the biosciences 1994;91:421-2
44. Hentrich M, Brack N, Schmid P, Jäger H, Jägel-Guedes E, Hartenstein R. HIV-Infektion und Keimzelltumoren des Hodens: 2 Kasuistiken. In: Jäger (Hrsg.) AIDS: Eine Krankheit wird behandelbar. (Ecomed Landsberg/Lech) 1993:123

Publizierte Kongress-Abstracts

1. Huebel K, Re A, Boumendil A, Finel H, Hentrich M, Michieli M, Kanfer E, Diez-Martin JL, Balsalobre P, Vincent L, Schroyens W, Ribera Santasusana JM, Kröger N, Schiel X, Thomson KJ, Sierra J, Sousa AB, Montoto S, Dreger P. [Autologous Stem Cell Transplantation \(autoSCT\) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy \(cART\): A retrospective analysis of the EBMT Lymphoma Working Party](#). Blood 2016;128(22):2256
2. Hentrich M, Debole J, Gerl A. Improved outcome of patients with metastatic germ cell tumors: results from a cohort study at two centers in Munich. Oncol Res Treat 2016;39(suppl 3):321(V1033)
3. Schreder M, Liebisch P, Hebart H, Holler E, Engelhardt M, Metzner B, Peest D, Aulitzky W, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Peschel C, Heß G, Hertenstein B, Wolf HH, Jung W, Frickhofen N, Maschmeyer G, Langer C, Meisner C, Kanz L, Einsele H, Knop S. Randomized comparison of pegylated IFN- α 2b versus IFN- α 2b maintenance following tandem autologous transplant in multiple myeloma. Oncol Res Treat 2016;39(suppl 3):163(P546)

4. Schalk E, Biehl LM, Färber J, Huth A, Panse J, Krämer C, Hentrich M, Engelhardt M, Schäfer-Eckart K, Kofla G, Kiehl M, Wendtner CM, Karthaus M, Cornely OA, Fischer T, Vehreschild MJGT. Prophylactic exchange of central venous catheters (CVC) for prevention of CVC-related bloodstream infections (CRBSI) in patients with haematological malignancies: indirect evidence from pooled data of the SECRECY registry and the COAT study. *Oncol Res Treat* 2016;39(suppl 3):8(V44)
5. Gerl A, Debole J, Hentrich M. Outcome of patients with metastatic germ cell cancer treated between 2000 and 2013 at two centers in Munich. *Ann Oncol* 2016;27(suppl. 6):vi289(836P)
6. Hentrich M, Gillor D, Müller M, Stöhr A, Schultze A, Jensen B, Wasmuth J-C, Wolf T, Siehl J, Oette M, Taylor N, Hensel M, Fätkenheuer G, Schommers P, Hoffmann C. Lymphoma-associated mortality in the German HIV-lymphoma cohort study. *J Clin Oncol* 2016;34(15suppl):7550
7. Hentrich M. Non-AIDS-defining malignancies: current therapeutic concepts. *Oncol Res Treat* 2015;38(Suppl5):41(V128)
8. Biehl LM, Huth A, Panse J, Hentrich M, Engelhardt M, Schäfer-Eckart K, Kofla, Kiehl M, Wendtner C, Karthaus M, Hellmich M, Christ H, Cornely OA, Vehreschild MJ. Chlorhexidine containing iv-catheter securement dressings for the prevention of central venous catheter-related bloodstream infections in neutropenic patients: A randomized trial (COAT study). *Oncol Res Treat* 2015;38(Suppl5):188(V618)
9. Hentrich M, Schommers P, Gillor D, Müller M, Stoehr A, Schultze A, Jensen, Wasmuth J-C, Wolf T, Siehl J, Oette M, Taylor N, Zinngrebe B, Hensel M, Horst H-A, Fätkenheuer G, Wyen C, Hoffmann C. Lymphoma-associated mortality in the German HIV-lymphoma cohort study. *Oncol Res Treat* 2015;38(Suppl5):198(V657)
10. Seidel Ca, Lorch A, Dieing A, Hentrich M, Hornig M, Grunwald V, Cathomas R, Meiler J, de Wit M, Bokemeyer C, Oechsle K. Efficacy and safety of gemcitabine, oxaliplatin and paclitaxel (GOP) in cisplatin-refractory germ cell tumors in routine care: Registry data from an outcomes research project. *J Clin Oncol* 2015;33(15suppl):e15570
11. Knop S, Liebisch P, Hebart H, Holler E, Engelhardt M, Metzner B, Peest D, Aulitzky W, Bunjes DW, Straka C, Fischer T, Wandt H, Sezer H, Hentrich M, Ostermann H, Peschel C, Hess G, Hertenstein B, Freund M, Kropff MH, Wolf HH, Jung WE, Frickhofen N, Bargou RC, Maschmeyer G, Heidemann E, Langer C, Kanz L, Meisner C, Einsele H. Autologous Followed By Allogeneic Versus Tandem-Autologous Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma. *Blood* 2014;124(21):43
12. Straka C, Schaefer-Eckart K, Bassermann F, Timon H, Hertenstein B, Langer C, Salwender H, Knop S, Engelhardt M, Kropff M, Roesler W, Decker T, Hebart H, Frickhofen N, Reichle A, Gerecke C, Metzner B, Heidemann E, Brümmendorf T, Ababei J, Jung WE, Gramatzki M, Hentrich M, Bojko P, von Metzler I, Kaufmann M, Naumann R, Kubin T, Schmidt B, Walther J, Dechow T, Wandt H, Schnabel B, Hinke A, Einsele H. Lenalidomide with low-dose dexamethasone (Rd) continuously versus Rd induction, tandem MEL140 with autologous transplantation and lenalidomide maintenance: planned interim analysis of a prospective randomized trial in patients 60-75 years of age with multiple myeloma. *Blood* 2014;124(21):3969
13. Oing C, Oechsle K, Necchi A, Loriot Y, De Giorgi U, Fléchon A, Daugaard G, Fedyanin M, Cohn-Cedermark G, Sava T, Lorch A, Winquist E, Gietema J, Hentrich M, Farè E, Bokemeyer C. Impact of bone metastases at initial diagnosis in male patients with metastatic germ cell tumors: Results from an international database. *Oncol Res Treat* 2014;37(Suppl 5):2(V25)

14. Schommers P, Wyen C, Hoffmann C, Gillor D, Zoufaly A, Jensen B, Bogner J, Thoden J, Wasmuth J-C, Wolf T, Oette M, Müller M, Esser S, Fätkenheuer G, Hentrich M. Survival of patients with AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma – results from the German HIV Lymphoma Cohort Study. *Oncol Res Treat* 2014;37(Suppl 5):34(V124)
15. Hentrich M. Central venous catheter-related infections – updated guidelines. *Oncol Res Treat* 2014;37(Suppl 5):36(V136)
16. Beyer J, Lorch A, Powles T, Kramar A, van Alstine L, Giannatempo P, Sava T, Albany C, Einhorn L, Flechon A, Aparicio J, Chung P, Huddart RA, Bokemeyer C, Tryakin A, Winquist E, Sweeney C, Hentrich M, Margolin K, Feldman DR. Brain metastases in male germ cell tumors (GCT): a large retrospective analysis on behalf of the SWENOTECA and the G3 Consortium. *Ann Oncol* 2014;25(Suppl 4):iv280–iv304(813PD)
17. Hentrich M, Wyen C, Gillor D, Hoffmann C, Zoufaly A, Wasmuth J-C, Mueller M, Wolf T, Siehl JM, Fätkenheuer G, Schommers P. Survival of patients with different AIDS-related lymphoma subtypes. *J Clin Oncol* 2014;32(15suppl):8548
18. Oing C, Oechsle K, Necchi A, Lorient Y, De Giorgi U, Fléchon A, Daugaard G, Fedyanin M, Cohn-Cedermark G, Sava T, Lorch A, Winquist E, Gietema J, Hentrich M, Farè E, Bokemeyer C. Bone metastases in germ cell tumors (GCT): Results from an international database. *J Clin Oncol* 2014;32(15suppl):4559
19. Fenner MH, Dieing A, Oechsle K, Hentrich M, Gauler TG, Lorch A, Kopp H-G, Beyer J, Bokemeyer C, Gruenwald V, Honecker F. A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer (RADIT). *J Clin Oncol* 2014;32(15suppl):e15535
20. Hentrich M. Treatment of patients with HIV-related germ cell tumors (GCT). *Onkologie* 2013;36(S7):88(V289)
21. Berger LA, Lorch A, Hentrich M, Kopp H-G, Gauler TC, Beyer J, de Wit M, Mayer F, Bokemeyer C, Honecker F, Kryselova N, Oechsle K. First-salvage treatment in patients with recurrent or refractory advanced germ cell cancer after cisplatin-based chemotherapy – a database of the German Testicular Cancer Study Group. *Onkologie* 2013;36(S7):113(V411)
22. Hentrich M, Oduncu F, Hennig J, Schmid P, Schiel X, Gerl A, Karthaus M. Mobilization of peripheral blood stem cells and autologous stem cell transplantation in HIV-related malignancies. *Onkologie* 2013;35(S7):234(P779)
23. Oechsle K, Berger LA, Lorch A, Hentrich M, Kopp H-G, Gauler TC, Beyer J, de Wit M, Honecker F, Bokemeyer C. First-salvage treatment in patients with recurrent or refractory advanced germ-cell cancer after cisplatin-based chemotherapy – a database of the German Testicular Cancer Study Group. *J Clin Oncol* 2013;31(Suppl):4459
24. Straka C, Schaefer-Eckart K, Bassermann F, Hertenstein B, Engelhardt M, Salwender H, Roesler W, Langer C, Schilling G, Knop S, Brümmendorf T, Metzner B, Hebart H, Reichle A, Frickhofen N, Heidemann E, Ababei J, Gerecke C, Jung WE, Gramatzki M, Decker T, Kropff M, Naumann R, Hentrich M, Walther J, Bojko P, Dechow T, Wandt H, Hinke A, Einsele H. Prospective randomized trial of Len/Dex induction followed by tandem MEL140 with autologous blood stem cell transplantation and Len maintenance versus continued therapy with Len/Dex in myeloma patients age 60–75 years: protocol-defined safety analysis after 100 patients. *Blood* 2012;120(21):2012
25. Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh J, Müller M, Fätkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schürmann D, Schmidmaier R, Knechten H, Planker M, Alt J, Mosthaf F, Engert A, Hoffmann C. Immunological effects during and after chemotherapy for HIV-related Hodgkin lymphoma. *Onkologie* 2012;35(S6):9

26. Hentrich M, Schmid M, Wiemer J, Will T, Karthaus M. Multiple organ dysfunction syndrome induced by oxaliplatin in a patient with metastatic colon cancer. *Onkologie* 2012;35(S6):206
27. Schommers P, Wyen C, Gillor D, Hentrich M, Zoufaly A, Jensen B, Bogner JR, Thoden J, Wasmuth JC, Fätkenheuer G, Hoffmann C. Poor outcome of HIV-infected patients with plasmablastic lymphoma – results from the German AIDS-related lymphoma (ARL) cohort study
28. Gerl A, Hauck A, Hentrich M. Can Abdominal Ultrasound Replace CT Scanning in Long-Term Follow-up of Male Patients with Germ Cell Tumor? *J Clin Oncol* 2012;30(15S):302s
29. Mounier N, Spina M, Re A, Wyen C, Tirelli U. Early determination of treatment sensitivity in HIV-related Hodgkin lymphoma by FDG-PET/CT after two cycles of ABVD chemotherapy. European Cooperative Study Group on AIDS and Tumors (GECAT study). *J Clin Oncol* 2012;30(15S):521s
30. Hentrich M, Berger M, Hoffmann C, Siehl J, Wolf T, Nickelsen M, Rockstroh J, Schürmann D, Rieke A, Schmidmaier R, Müller M, Engert A, Kingreen D, Knechten H, Mosthaf F, Planker M, Arastéh K, Wyen C. PET scans in HIV-related Hodgkin's lymphoma (HIV-HL): results of a retrospective study. *Onkologie* 2011;34(S6):135
31. Motzke C, Frick E, Kälberer-Dychenko Y, Kinzel C, Kohnert M, Ebel K, Schmidmaier R, Baumann P, Straka C, Hentrich M, Menzel H, Padberg F, Oduncu F, Bumeder I. Comparison of emotional well being, perceived social support and quality of life of patients undergoing autologous peripheral blood stem cell transplantation (PBSCT) and their caregivers: a one year longitudinal investigation. *Onkologie* 2011;34(S6):108
32. Knop S, Liebisch P, Hebart H, Holler E, Engelhardt M, Bargou RC, Metzner B, Dölken G, Peest D, Aulitzky W, Bunjes D, Straka C, Wandt H, Sezer O, Hentrich M, Ostermann H, Dechow T, Heß G, Hertenstein B, Freund M, Kropff M, Wolf H, Jung W, Frickhofen N, Maschmeyer G, Mergenthaler H, Kanz L, Meisener C, Einsele H, Deutsche Studiengruppe Multiples Myelom (DSMM). Up front allogeneic stem cell transplant is superior to tandem high-dose melphalan in cytogenetically defined ultra high-risk myeloma. *Onkologie* 2011;34(S6):199-200
33. Hentrich M, Berger M, Hoffmann C, Siehl J, Rockstroh J, Wolf T, Müller M, Nickelsen M, Schürmann D, Rieke A, Schmidmaier R, Engert A, Mosthaf F, Fätkenheuer G, Arastéh K, Wyen C, German HIV-Related Lymphoma Study Group. HIV-associated Hodgkin's lymphoma (HIV-HL): results of a prospective multicenter trial. *Haematologica* 2011;96(S2):s2(0519)
34. Hentrich M, Berger M, Hoffmann C, Siehl J, Wolf T, Nickelsen M, Rockstroh J, Schürmann D, Rieke A, Schmidmaier R, Knechten H, Mueller M, Faetkenheuer G, Meyer R, Arasteh K, Mosthaf F, Wyen C. PET scans in HIV-related Hodgkin lymphoma (HIV-HL): results of a retrospective study. *J Clin Oncol* 2011;29(Suppl):515s
35. Hentrich M, Schiel X, Oduncu F, Gerl A, Karthaus M. Mobilization of Peripheral Blood Stem Cells and Autologous Transplantation in HIV-related Malignancies. *Bone Marrow Transplant* 2011;46(S1):S253
36. Hentrich M, Schiel X, Oduncu F, Gerl A, Scheidegger C, von Schilling C, Lutz L, Karthaus M. Peripheral Blood Stem-Cell Mobilisation and Autologous Stem Cell Transplantation In HIV-Related Malignancies. *Blood* 2010;116(Suppl):4592
37. Morris C, Scholten M, de Wreede L, van Biezen A, Dickmeiss E, Trneny M, Apperley J, Chiusolo P, Van Imhoff G, Lenhoff S, Uharek L, Martinelli G, Hentrich M, Sureda A, de Witte T, Ruutu T. DMSO Reduction Strategies Reduce DMSO Induced Post Autologous Transplant Morbidity In Patients with Lymphoma and Myeloma –Results from an EBMT Non Interventional Prospective Study. *Blood* 2010;116(Suppl):2397

38. Ribera JM, Wyen C, Morgades M, Hoffmann C, Oriol A, Fätkenheuer G, Grande C, Mueller M, Esteve J, Wasmuth J-C, Del Potro E, van Lunzen J, Brunet S, Knechten H, Escoda L, Hammond A, Alonso N, Hentrich M, Vall-Ilovera F, Mayr C, Perez M, Thoden J, Garcia O, Sternfeld T, Wolf T, Sanz MA, Hoelzer D. Specific Chemotherapy and Rituximab In HIV-Infected Patients with Burkitt's Leukemia or Lymphoma. Results of a German-Spanish Study and Analysis of Prognostic Factors. *Blood* 2010;116(Suppl):3944
39. Hentrich M, Schiel X, Pohlmann H, Schmid P, Karthaus M, Gerl A. Brain metastases in malignant germ cell tumours: Results from a two-institutional cohort study. *Onkologie* 2010;33(S6):59-60
40. Rölling C, Brandts C, Shaid S, Hentrich M, Krämer A, Junghanß C, Schleyer , Müller-Tidow C, Ritter B, Pflüger K-H, Kramer M, Haibach M, Berdel WE, Serve H, Ehninger G, Krause SW, Study Alliance SAL. Survey on the prescription pattern and efficacy of sorafenib in patients with acute myeloid leukemia. *Onkologie* 2010;33(S6):140
41. Motzke C, Kälberer_Dychenko Y, Kinzel C, Kohnert M, Ebelt K, Schmidmaier R, Baumann P, Frick E, Straka C, Hentrich M, Menzel H, Padberg F, Oduncu F, Bumeder I. Comparative analysis of quality of life and distress of patients and their partners prior to high-dose chemotherapy and autologous blood stem cell transplantation (ABSCT). Impact of disease and therapy on patients and their partners. *Onkologie* 2010;33(S6):179
42. Hentrich M, Berger M, Hoffmann C, Siehl J, Wolf T, Rockstroh J, Fätkenheuer G, Arastéh K, Mosthaf F, Wyen C, for the German HIV-Related Lymphoma Study Group. HIV-associated Hodgkin's lymphoma (HIV-HL): Results of a prospective multicenter trial. *J Clin Oncol* 2010;28(15S):581s
43. Hentrich M, Arastéh K, Wyen C, Siehl J, Wolf T, Rieke A, Rockstroh J, Schürmann D, Berger M, Meyer A, Sabranski M, Bogner J, Mostaf F, Fätkenheuer G, Hoffmann C. HIV-associated Hodgkin's lymphoma (HIV-HL): Interim analysis of a prospective multicenter trial. *HIV Medicine* 2009;10(S2):6
44. Wyen C, Jensen B, Wolf T, Müller M, Sabranski M, Siehl J, Esser S, Thoden J, Wasmuth J-C, Ross B, van Lunzen J, Hentrich M, Fätkenheuer G, Hoffmann C. Treatment of HIV-associated lymphoma in the era of highly active antiretroviral therapy: results of the German HIV-Lymphoma Cohort. *HIV Medicine* 2009;10(S2):37
45. Knop S, Liebisch P, Hebart H, Holler E, Engelhardt M, Bargou RC, Metzner B, Peest D, Aulitzky WE, Wandt H, Sezer O, Hentrich M, Ostermann H, Peschel C, Hess G, Hertenstein B, Freund M, Kropff MH, Wolf H-H, Jung W, Frickhofen N, Maschmeyer G, Mergenthaler H-G, Heidemann E, Kröger N, Straka C, Engel C, Kanz L, Meisner C, Einsele H. Allogeneic Stem Cell Transplant Versus Tandem High-Dose Melphalan for Front-Line Treatment of Deletion 13q14 Myeloma – An Interim Analysis of the German DSMM V Trial. *Blood* 2009;114(Suppl):51
46. Dreger P, Döhner H, Greinix H, McClanahan F, Hensel M, Hertenstein B, Dührsen U, Hentrich M, Trümper L, Sonnen R, Emmerich B, Knauf W, Hopfinger G, Hallek M, Kneba M, Schmitz N, Stilgenbauer S for the German CLL Study Group. Early autologous stem cell transplantation (autoSCT) may overcome the adverse impact of del 11q- in poor-risk chronic lymphocytic leukemia (CLL): Results from the GCLLSG CLL3 Trial. *Blood* 2009;114(Suppl):879
47. Hentrich M, Gerl A, Lutz L, Karthaus M, Schiel X. Rituximab-containing therapy for Non-Hodgkin's Lymphoma: opportunistic infections and unexpected toxicity. *Onkologie* 2009;32(S4):156-7
48. Hentrich M, Berger M, Wolf T, Siehl J, Wasmuth JC, Assmann D, Schürmann D, Nickelsen M, Meyer A, Mostaf F, Arastéh K, Fätkenheuer G, Engert, A, Hoffmann C, Wyen C. HIV-related Hodgkin's lymphoma (HIV-HL): Interim analysis of a prospective multicenter trial. *Onkologie* 2009;32(S4):49

49. Hentrich M, Oduncu F, Gerl A, Scheidegger C, v. Schilling C, Bogner J, Karthaus M, Lutz L, Schiel X. High dose chemotherapy followed by autologous peripheral blood stem cell transplantation in HIV-related malignancies. *Onkologie* 2009;32(S4):194
50. Hoffmann C, Fätkenheuer G, Reuter S, Sabranski M, Rockstroh J, van Lunzen J, Mayr C, Esser S, Hentrich M, Thoden J, Wyen C. Treatment of HIV-associated lymphoma in the era of highly active antiretroviral therapy – preliminary results of the German HIV-Lymphoma Cohort. *Onkologie* 2009;32(S4):156
51. Hentrich M, Masuhr A, Wyen C, Siehl J, Rieke A, Wasmuth JC, Wolf T, Assmann D, Meyer A, Nickelsen M, Schürmann D, Mostaf F, Arastéh K, Fätkenheuer G, Hoffmann C. HIV-associated Hodgkin's lymphoma (HIV-HL): Interim analysis of a prospective multicenter trial. *Eur J Med Res* 2009;14(S1):12
52. Hentrich M, Röhnisch T, Gerl A, Scheidegger C, Jaegel-Guedes E, v. Schilling C, Sternfeld T, Schiel X. High dose chemotherapy followed by autologous peripheral blood stem cell transplantation in HIV-related lymphoma or germ cell tumor: the Munich experience *Eur J Med Res* 2009;14(S1):90
53. Wyen C, Fätkenheuer G, Jensen B-EO, Sabranski M, Wolf T, Siehl J, Ross B, Müller M, Rockstroh J, van Lunzen J, Esser S, Hentrich M, Hoffmann C. Outcome of AIDS-related lymphoma depends on CD20 expression. *Eur J Med Res* 2009;14(S1):11
54. Hentrich M, Gerl A, Lutz L, Karthaus M, Schiel X. Unexpected toxicity (UT) and opportunistic infections (OI) after Rituximab-containing therapy for Non-Hodgkin's Lymphoma (NHL). *J Clin Oncol* 2009;27(15s):e19546
55. Hentrich M, Methfessel I, Hoffmann U, Lutz L, Schiel X. Pulmonary complications after Rituximab-containing therapy for Non-Hodgkin's Lymphoma. *Onkologie*2008;31(S4):154
56. Hentrich M, Drauz D, Wyen C, Hoffmann C, Mosthaf F, Wasmuth JC, Wolf, Kloenne U, Assmann D, Nickelsen M, Fong D, Schürmann D, Arastéh K, Engert A, Mitrou P. HIV-associated Hodgkin's disease (HIV-HD): Interim analysis of a prospective multicenter trial. *Onkologie*2008;31(S4):177
57. Hentrich M, Meiler S, Fegg MJ, Gerl A. Changes in sexual functioning after germ cell tumor therapy estimated by patients and their partners. *J Clin Oncol* 2008;26(15S):271s
58. Wyen C, Fätkenheuer G, Oette M, Plettenberg A, Rockstroh J, van Lunzen J, Mayr C, Esser S, Hentrich M, Hoffmann C. Treatment of AIDS-relates lymphoma: rituximab may be beneficial even in severely immunosuppressed patients. 15th conference on retroviruses and opportunistic infections 2008:Q107
59. Balsalobre P, Diez-Martin JL, Re A, Michieli MG, Ribera J-M, Rosselet A, Conde E, Varela R, Cwynarski K, Gabriel I, Genet P, Guillerm G, Allione B, Ferrant A, Hentrich M, Biron P, Meyer D, Espigado I, Hunter AE, Jurado M, Fernandez P, Canals C, Taghipour G, Serrano D, Sureda A, on behalf of the EBMT Lymphoma Working Party. Autologous stem cell transplantation (ASCT) in HIV associated Lymphoma (HIV-Ly) patients: An updated analysis of the EBMT Lymphoma Working Party (EBMT-LWP) Experience. *Blood* 2007;110(Suppl):1887
60. Diez-Martin JL, Balsalobre P, Re A, Biron P, Conde E, Rosselet A, Allione B, Espigado I, Genet P, Ribera J-M, Ferrant A, Gillerme G, Meyer D, Rupolo M, Varela R, Hentrich M, Hunter AE, Canals C, Taghipour G, Serrano D, Sureda A, on behalf of the EBMT Lymphoma Working Party. Comparable Survival between HIV+ and HIV- Hodgkin's Lymphoma (HL) and Non-Hodgkin's Lymphoma (NHL) patients undergoing an autologous peripheral blood stem cell transplantation (ASCT). A retrospective analysis of the EBMT Lymphoma Working Party. *Blood* 2007;110(Suppl):24

61. Straka C, Liebisch P, Hennemann B, Metzner B, Salwender H, Kanz L, Adler-Reichel S, Ludwig WD, Wandt H, Bentz M, Bruemmendorf T, Hentrich M, Trümper L, Freund M, Wolf HH, Sezer O, Bargou R, Doelken G, Schmitz N, Bernhard H, Gramatzki M, Frickhofen N, Ostermann H, Schmidmeier R, Ibach S, Hinke A, Einsele H, Emmerich B. The effects of induction chemotherapy and high-dose melphalan with tandem autologous transplantation in multiple myeloma: the prospective randomized DSMM 2 study. *Blood* 2007;110(Suppl):446
62. Hentrich M, Masuhr A, Hoffmann C, Schürmann D, Rockstroh J, Kloenne U, Weiss R, Knechten H, Wolf T, Mosthaf F, Arastéh K, Fätkenheuer G, Engert A, Mitrou P, Wyen C. Treatment of HIV-associated Hodgkin's disease (HIV-HD): Interim analysis of a prospective multicenter trial. *Haematologica* 2007;92(S5):56
63. Hentrich M, Kreckel P, Wyen C, Schürmann D, Kloenne U, Mosthaf F, Buhk T, Fong D, Meyer R, Arastéh K, Engert A, Fätkenheuer G, Mitrou P, Hoffmann C. Treatment of HIV-associated Hodgkin's disease (HIV-HD): Interim analysis of a prospective multicenter trial. *Eur J Med Res* 2007;12(SII):53-4
64. Hoffmann C, Wyen C, Mayr C, Plettenberg A, Oette M, van Lunzen J, Rockstroh J, Esser S, Jäger H, Horst HA, Hentrich M, Mosthaf F, Greiffendorf I, Hammond A, Fätkenheuer G, German ARL Cohort Study Group. Current trends in AIDS-related lymphoma (ARL) – preliminary results of the German ARL Cohort Study. *Eur J Med Res* 2007;12(SII):54
65. Schmid C, Schleuning M, Tischer J, Ledderose G, Gerbitz A, Oruzio D, Hentrich M, Kolb H. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high risk acute myeloid leukemia in first complete remission. *Bone Marrow Transplant* 2007;39(S1):S6
66. Balsalobre P, Serrano D, Re A, Rosselet A, Conde E, Ribera J, Allione B, Guillerme G, Genet P, Espigado I, Hunter AE, Hentrich M, Biron P, Ferrant A, Meyer D, Sureda A, Diez-Martin JL, on behalf of the EBMT Lymphoma Working Party. Autologous stem cell transplantation (ASCT) in HIV associated lymphoma (HIV-Ly) patients: the EBMT Lymphoma Working Party (EBMT-LWP) Experience. *Blood* 2006;108(Suppl):3042
67. Lorenzen S, Weigert N, Heinemann V, Hentrich M, Hollweck R, Seroneit T, Röthling N, Peschel C, Lordick F. Docetaxel (T) plus cisplatin (P) and leukovorin/5-FU (LF) in 1st line advanced gastric cancer and adenocarcinoma of the esophago-gastric junction: results of the multicenter phase II GASTRO-TAX-1 trial. *Ann Oncol* 2006;17(S9):ix312
68. Lorenzen S, Weigert N, Heinemann V, Hentrich M, Hollweck R, Seroneit T, Röthling N, Peschel C, Lordick F. Docetaxel plus cisplatin and leukovorin/5-FU in first-line advanced gastric cancer and adenocarcinoma of the esophago-gastric junction: results of the multicenter phase II GASTRO-TAX-1 trial. *Onkologie* 2006;29(S3):12-3
69. Hentrich M, Ostermann H, Fehnle K, Kienast J, Cornely O, Salat C, Übelacker R, Buchheidt D, Behre G, Hiddemann W, Schiel X. A prospective randomized controlled trial of IgGMA-enriched immunoglobulin in neutropenic cancer patients with sepsis syndrome and septic shock. *Onkologie* 2006;29(S3):63
70. Hentrich M, Hoffmann U, Pohlmann H, Reitmeier M, Scheidt B, Hartenstein R, Lutz L. A rare case of tumor lysis syndrome after therapy with oxaliplatin/5-FU/folinic acid and bevacicumb in a patient with multiples relapses of colon cancer. *Onkologie* 2006;29(S3):143-4
71. Hentrich M, Kreckel P, Wyen C, Schürmann D, Krümpelmann A, Nickelsen M, Meyer R, Kingreen D, Arastéh K, Fätkenheuer G, Hoffmann C, Engert A, Mitrou P. Treatment of HIV-associated Hodgkin's disease (HIV-HD): First results of a prospective multicenter trial. *Onkologie* 2006;29(S3):170-1

72. Hentrich M. HIV-associated Non Hodgkin`s Lymphoma. JDDG 2006;4(9):794
73. Hentrich M, Ledderose G, Lutz L, Tischer J, Gerl A, Hartenstein R., Kolb HJ. Hematopoietic stem cell transplantation (HSCT) in patients with primary granulocytic sarcoma (GS). J Clin Oncol 2006;24(Suppl):666s
74. Hentrich M, Schmid P, Scheidegger C, Jaegel-Guedes E, Lutz L. A case of autologous stem cell transplantation in refractory HIV-associated diffuse large cell lymphoma. Bone Marrow Transplant 2006;37(S1):S345
75. Lorenzen S, Duyster J, Weigert N, Heinemann V, Hentrich M, Hennig M, Seroneit T, Röthling N, Peschel C, Lordick F. Docetaxel, cisplatin and leukovorin/5-FU in 1st line advanced gastric cancer and adenocarcinoma of the esophago-gastric junction: first results of the phase II Gastro-Tax-1 trial. ASCO-GI 2006:66
76. Kropff M, Bisping G, Liebisch P, Sezer O, Einsele H, Straka C, Kroeger N, Metzner B, Engelhardt M, Lang N, Hentrich M, Wolf H, von Schilling C, Salwender H, Berdel W, Kienast J. Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Blood 2005;106(Suppl):716a
77. Hentrich M, Neuhoff P, Marreta L, Bogner J, Schürmann D, Jäger H, Reichelt D, Rockstroh J, Ruhnke M, Scheidegger C, Oette M, Weiß R, Mitrou P. Improved survival in HIV-associated Hodgkin`s disease in the era of highly active antiretroviral therapy (HAART). Onkologie 2005;28(S3):173
78. Lordick F, Lorenzen S, Vehling-Kaiser U, Kullmann F, Hentrich M, Zumschlinge R, Dietzfelbinger H, Seroneit T, Bredenkamp R, Duyster J, Peschel C. Phase II study of weekly oxaliplatin plus infusional fluorouracil and flonic acid (FUFOX regimen) as first line treatment in metastatic gastric cancer. Onkologie 2005;28(S3):240
79. Hentrich M, Hennig J, Lutz L, Gerl A, Hartenstein R. Salvage high dose chemotherapy with autologous stem cell transplantation in recurrent adult neuroblastoma. Onkologie 2005;28(S3):266
80. Dreger P, Stilgenbauer S, Busch R, Greinix H, Hensel M, Hertenstein B, Dührsen U, Flashhove M, Hentrich M, Glass B, Ritgen M, Kneba M, Schmitz N, Hallek M, Döhner H. Early sequential high-dose therapy in genetically poor-risk chronic lymphocytic leukemia: results from the GCLLSG CLL3 protocol. Onkologie 2005;28(S3):29
81. Hentrich M, Maretta L, Bogner J, Schürmann D, Jäger H, Reichelt D, Rockstroh J, Ruhnke M, Scheidegger C, Oette M, Weiß R, Neuhoff P, Mitrou P. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin`s disease. Haematologica 2005;90(S2):142
82. Hentrich M, Fegg M, Jost Ch, Meiler S, Gerl A. Smoking Cessation in Long-Term Survivors of Germ Cell Tumor (GCT). J Clin Oncol 2005;23(Suppl):437s
83. Duyster J, Lorenzen S, Kullmann F, Hentrich M, Zumschlinge R, Vehling-Kaiser U, Seroneit T, Bredenkamp R, Peschel C, Lordick F. Oxaliplatin plus 5FU/folinic acid (FUFOX regimen) in 1st line metastatic gastric cancer (MGC). Results of the multicenter phase II STOMOX trial. J Clin Oncol 2005;23 (Suppl):311s
84. Dreger P, Stilgenbauer S, Busch R, Greinix H, Hensel M, Hertenstein B, Dührsen U, Hentrich M, Glass B, Ritgen M, Emmerich B, Hallek M, Kneba M, Schmitz N, Döhner H, on Behalf of the German CLL Study group. High 34-cell yields and low rate of secondary MDS/AML using intensive mobilisation for early autologous stem cell transplantation in genetically poor-risk CLL: results from a prospective multicenter study (GCLLSG CLL3 Protocol). Bone Marrow Transplant 2005;35(Suppl 2):S67

85. Dreger P, Busch R, Stilgenbauer S, Greinix H, Hensel M, Hertenstein B, Duehrsen U, Hentrich M, Truemper LH, Schmitz N, Ritgen M, Emmerich B, Hallek MJ, Kneba M, Dohner H. German CLL Study Group, (GCLLSG). Early autologous stem cell transplantation (SCT) in genetically poor-risk chronic lymphocytic leukemia is feasible and effective: Results from a prospective multicenter study (GCLLSG CLL3 protocol). *Blood* 2004;104(Suppl):146
86. Hentrich M, Gerl A, Weber N, Schlemmer M, Hartenstein R, Hiddemann W. Late relapse in patients with germ cell tumors (GCT) after cisplatin-based chemotherapy. *Onkologie* 2004;27(S3):145
87. Lordick F, Lorenzen S, Stollfuss J, Vehling-Kaiser U, Kullmann F, Hentrich M, Dietzfelbinger H, Zumschlinge R, Duyster J, Peschel C. Weekly oxaliplatin plus 5-FU/folinic acid (FUFOX regimen) in metastatic gastric cancer,. Results of the STOMOX phase II trial of the Munich Center for Clinical Studies cooperative network. *Ann Oncol* 2004;15 (S3):iii235
88. Witzig R, Lordick F, Schoenberger B, Guendel H, Bredenkamp R, Hentrich M, Fink U, Busch R, Peschel C, Siewert JR. Delays in diagnosis and therapy of gastric cancer. *Ann Oncol* 2004;15 (S3):iii236
89. Gerl A, Hentrich M, Weber N, Schlemmer M, Hartenstein R, Hiddemann W. Clinical characteristics and outcome of late relapse after cisplatin-based chemotherapy of germ cell tumor. An update. *Proc ASCO* 2004;23:387
90. Hentrich M, Weber B, Bergsdorf T, Liedl B, Hartenstein R, Gerl A. Management and outcome of patients with bilateral testicular germ cell tumors (TGCT). *J Cancer Res Clin Oncol* 2004;130(S1):S108
91. Hentrich M, Weber B, Bergsdorf T, Liedl B, Hartenstein R, Gerl A. Bilateral testicular germ cell tumors (TGCT). A report on 41 patients (pts). *Proc ASCO* 2003;22:406
92. Hentrich M, Brack N, Pohlmann H, Schmid P, Lutz L, Hartenstein R. Successful salvage high dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) in a patient with five relapses of Hodgkin's disease. *Onkologie* 2002;25(S4):7
93. Lordick F, Hentrich M, Bernhard H, v Schilling C, Gadenz-Teichen C, Pohlmann H, Mundel M, Schwarz K, Kappstein I, Peschel C, Hartenstein R, Decker T. Ultrasound screening for central venous catheter-related thrombosis proves helpful in the detection and prevention of catheter-related infections in patients with hemato-oncological malignancies. *Hematol J* 2002;3(S1):115
94. Hentrich M, Göbel C, Pohlmann H, Brack N, Lutz L, Bergsdorf T, Schorer H, Hartenstein R. Therapy and outcome of patients with testicular germ cell tumors (GCT): a single center experience. *Onkologie* 2001;24(S6):167
95. Hentrich M, Munker R, Pohlmann H, Brack N, Hartenstein R. A case of HIV-associated B-ALL successfully treated by intensive chemotherapy (B-ALL protocol). *Onkologie* 2001;24(S6):41
96. Hentrich M, Oruzio D, Jäger G, Schleuning M, Stötzer O, Hartenstein R, Hiddemann W, Kolb HJ. Human herpesvirus-6 (HHV6) after hematopoietic stem cell transplantation (HSCT). *Proc ASCO* 2001;20:11a
97. Stötzer O, Ledderose G, Schleuning M, Gerl A, Hentrich M, Beckert B, Tischer J, Hiddemann W, Kolb HJ. Sequence of an autologous transplantation followed by an allogeneic stem cell transplantation in the treatment of multiple myeloma. *Proc ASCO* 2001;20:4b
98. Hentrich M, Oruzio D, Jäger G, Schleuning M, Stötzer O, Schlemmer M, Kolb HJ. Human herpes virus-6 (HHV6) in patients after hematopoietic stem cell transplantation (HSCT). *Bone Marrow Transplant* 2001;24(S1):S199

99. Hentrich M, Brack N, Hoffmann U, Sandner R, Hartenstein R. A case of adult neuroblastoma. *Onkologie* 2000;23(S7):184
100. Hentrich M, Jäger G, Schlemmer M, Schleuning M, Stötzer O, Braess J, Hiddemann W, Kolb HJ. Human herpesvirus-6 (HHV6) after hematopoietic stem cell transplantation (HSCT). *Onkologie* 2000;23(S7):164
101. Oruzio D, Stötzer D, Hentrich M, Pfannes W, Öttrich K, Schoch C, Kolb HJ. T-cell chimerism after allogeneic hematopoietic stem cell transplantation. *Onkologie* 2000;23(S7):121
102. Schleuning M, Jäger G, Stötzer O, Hentrich M, Hiddemann W, Kolb HJ. Preliminary results of a prospective parvo B19 surveillance study in hematopoietic stem cell transplantation. *Onkologie* 2000;23(S7):17
103. Stötzer O, Schleuning M, Koch G, Ledderose G, Hill W, Hentrich M, Schlemmer M, Pfannes W, Kolb HJ. Fas-ligand serum levels after bone marrow transplantation. *Onkologie* 2000;23(S7):133
104. Salat C, Vogeser M, Kolb HJ, Pihusch R, Pihusch M, Hentrich M, Schlemmer M, Hiller E. Procollagen III peptide levels in patients with hyperbilirubinemia after haematopoietic stem cell transplantation. *Ann Hematol* 2000;79(S1):A18
105. Hentrich M, Steglich J, Brack N, Hartenstein R. Wilms tumor in adults. *Onkologie* 1999;22(S1):217
106. Hentrich M, Brack N, Schmid P, Meister P, Hartenstein R. Late relapse in a patient with Ewing sarcoma. *Onkologie* 1999;22(S1):119
107. Hentrich M, Sandner R, Brack N, Hartl H, Hartenstein R. HIV-Infektion und akute myeloische Leukämie (AML). *Eur J Med Res* 1999;4(S1):48
108. Hentrich M, Brack N, Göbel C, Pohlmann H, Lutz L, Hartenstein R. Second relapse in patients with germ cell tumors (GCT) after successful salvage chemotherapy or surgery. *Proc ASCO* 1999;18:341a
109. Hentrich M, Brack N, Hartenstein. Secondary promyelocytic leucemia following etoposide containing chemotherapy for germ cell tumors (GCT). *Proc ASCO* 1998;17:333a
110. Hentrich M, Brack NB, Schuster T, Clemm Ch, Hartenstein R. Germ cell tumors (GCT) in men with HIV infection. *Eur J Cancer* 1997;33(S8):S41
111. Gerl A, Hentrich M, Clemm C, Hartenstein R, Schuster T, Wilmanns W. Bilateral testicular germ cell tumors (TGCT). *Eur J Cancer* 1997;33(S8):S40-41
112. Gerl A, Hentrich M, Clemm C, Hartenstein R, Schuster T, Wilmanns W. Characteristics and outcome of bilateral testicular germ cell tumors (TGCT). *Proc ASCO* 1997;16:322a
113. Clemm C, Gerl A, Hentrich M, Knutzen B, Gassel WD, Wilmanns W. Chemotherapy in far advanced seminoma. *Eur J Cancer* 1995;31A(S5):S189
114. Gerl A, Clemm C, Hartenstein R, Hentrich M, Wilmanns W. Prognosis after salvage treatment of germ cell tumors. *Proc ASCO* 1995;14:252
115. Clemm C, Gerl A, Hentrich M, Wilmanns W. Combination chemotherapy in bulky seminoma. *Ann Oncol* 1994;5(S8):69
116. Clemm C, Gerl A, Hentrich M, Kohl P, Knutzen B, Hartenstein R, Gassel WD, Wilmanns W. Cisplatin-containing chemotherapy in bulky seminoma. *J Cancer Res Clin Oncol* 1994;120 (Suppl):R9

117. Clemm C, Gerl A, Kohl P, Hentrich M, Hartenstein R, Gassel WD, Knutzen B, Wilmanns W. Combination chemotherapy containing cisplatin/ifosfamide and vinblastine or etoposide in bulky seminoma. *Eur J Cancer* 1993;29A(S6):240
118. Hentrich M, Brack N, Sandner R, Lutz L, Jäger H, Hartenstein R. Testicular germ cell cancer (GCT) and HIV infection: 2 case reports. Xth International Conference on AIDS 1993:412
119. Gerl A, Clemm C, Hartenstein R, Hentrich M, Wilmanns W. Long term outcome after chemotherapy for advanced metastatic non-seminomatous germ cell tumors. *Proc ASCO* 1993;12:236
120. Gerl A, Clemm C, Hentrich M, Hartenstein R, Kohl P, Wilmanns W. Chemotherapy for advanced metastatic non-seminomatous germ cell tumors with etoposide, cisplatin, bleomycin and cyclophosphamide. *Ann Haematol* 1992;65(Suppl):A59
121. Gerl A, Clemm C, Hentrich M, Hartenstein R, Wilmanns W. Etoposide, cisplatin, bleomycin, and cyclophosphamide (ECBC) as first line chemotherapy for poor-risk nonseminomatous germ cell tumors. *Ann Oncol* 1992;65(S5):164
122. Clemm C, Gerl A, Kohl P, Hentrich M, Hartenstein R, Wilmanns W. Cisplatin-containing chemotherapy in bulky seminoma. *Ann Oncol* 1992;3(S5):166
123. Hentrich M, Peikert A, Ochs G, Hartenstein R. Topical capsaicin and postherpetic neuralgia. *Onkologie* 1991;14(S3):21
124. Ochs GA, Hentrich M, Peikert A. Topical capsaicin is effective in 50% of patients with postherpetic neuralgia. *J Neurol* 1990;237(S1):62